NRx Pharmaceuticals to Unveil 2025 Results, Update on Breakthrough Psychiatric Drug Pipeline
NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.
NRXPNRXPWfinancial resultsclinical-stage biopharmaceutical